-
Study aim
-
Determining the effects of vitamin D in patients with benign paroxysmal positional vertigo
-
Design
-
Clinical trial with control and intervention groups,
On100 patients,
Randomized with a random number table,
Not blinded
-
Settings and conduct
-
Patients with benign paroxysmal positional vertigo (BPPV) who refer to Baqiyatallah Hospital during the study will be included in the study if they are eligible and will be randomly assigned to two intervention and control groups using a random number table method. Blinding was not performed in this study.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with confirmed benign paroxysmal positional vertigo, over 18 years of age, vitamin D levels between 30 and 50.
Exclusion criteria: Failure to complete the informed consent form, Taking drugs that affect vitamin D metabolism, History of ear surgery, History of Meniere's disease, History of labyrinthitis or vestibular neuritis, Pregnancy or breastfeeding
-
Intervention groups
-
In the intervention group, in addition to standard BPPV treatment (Epley maneuver It is a treatment method performed by a physician and involves a series of four head and body movements from sitting to lying down, rolling to the side, and returning to a sitting position.), one 1000-unit vitamin D supplement tablet (Dana Pharma) is prescribed once daily with food until the end of the study (6 months). The dose of vitamin D used in this study is within the daily requirement and completely safe.
In the control group , only the Epley therapeutic maneuver is performed, This is the approved standard treatment and it is recommended that patients not take vitamin D supplements until the end of the study.
-
Main outcome variables
-
the number of benign paroxysmal positional vertigo (BPPV) attacks, the time interval between BPPV attacks, BPPV attack duration, severity of BPPV attacks, symptoms associated with BPPV